Stock comparison
Haemonetics
Kiniksa Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
KNSA
Kiniksa Pharmaceuticals
Market cap
$4B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | KNSA | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 39D | HAE |
| Benjamin Graham | 85A | 72D | HAE |
| Philip Fisher | 60C | 56C | HAE |
| Peter Lynch | 54C | 36D | HAE |
| Joel Greenblatt | 31F | 52D | KNSA |
| Charlie Munger | 54D | 39D | HAE |
| Terry Smith | 55D | 35D | HAE |
Side-by-side metrics
| Metric | HAE | KNSA |
|---|---|---|
| Market cap | $2.98B | $4B |
| P/E (TTM) | 24.8x | 61.4x |
| EV/EBIT | 14.1x | 54.7x |
| ROIC (TTM) | 8.37% | 9.56% |
| Gross margin | 55.74% | 54.63% |
| Net margin | 7.29% | 9.69% |
| Revenue CAGR 5y | 7.65% | 104.76% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 54.7x+74%
- P/E (TTM)24.8xvs 61.4x+60%
KNSA leads on
- Debt / Equity0.0xvs 1.5x+99%
- Revenue CAGR 5y104.76%vs 7.65%+93%
- Market cap$4Bvs $2.98B+26%
- Net margin9.69%vs 7.29%+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.